FDA Warning Letter Explorer
Drugs · Letter issue date: Oct 26, 2026

Ong Tien USA LLC

2 extracted findings

FDA source excerpt, selected passage

Based on a review of your website and product label, respectively, “Sâm Xương Khớp Tế Bào Gốc Linh Chi Ông Tiên,” “Sâm Xương Khớp Ông Tiên,” and “Cao Đông Trùng Hạ Thảo Tế Bào Gốc Linh Chi” are drugs under section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and/or intended to affect the structure or any function of the body.

Findings and supporting evidence

Model-assisted readings, not an exhaustive interpretation. Compare with the extracted source findings below.

Findings extracted from the letter

Selected FDA passages, not the complete letter.

01
Based on a review of your website and product label, respectively, “Sâm Xương Khớp Tế Bào Gốc Linh Chi Ông Tiên,” “Sâm Xương Khớp Ông Tiên,” and “Cao Đông Trùng Hạ Thảo Tế Bào Gốc Linh Chi” are drugs under section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and/or intended to affect the structure or any function of the body.
02
The labeling for your “Sâm Xương Khớp Ông Tiên” product does not declare that it contains piroxicam or dexamethasone phosphate. As previously mentioned, FDA confirmed through laboratory analysis that your product contains piroxicam and dexamethasone phosphate.

Sections and clauses cited

As cited in this historical letter, not a statement of current regulatory requirements.

Keep exploring

For regulated teams

Put this kind of reading to
work on your own records.

Botable builds and runs a custom AI layer around the software you already use, so your team can do the job you hired them for.

FDA Warning Letter Alerts

Share this view

Send the same filters, search and view to a colleague.

You choose what to post or send. Sharing a link does not change access to this site.